Article
Medicine, General & Internal
Zhicheng Lai, Yexing Huang, Dongsheng Wen, Xuanjia Lin, Anna Kan, Qijiong Li, Wei Wei, Minshan Chen, Li Xu, Minke He, Ming Shi
Summary: This study compared the efficacy and safety of one-day and two-day HAIC regimens in treating hepatocellular carcinoma (HCC) and explored the predictive power of thymidylate synthase (TYMS).
Article
Oncology
Khalid Jazieh, Mohammadhadi Khorrami, Anas Saad, Mohamed Gad, Amit Gupta, Pradnya Patil, Vidya Sankar Viswanathan, Prabhakar Rajiah, Charles J. Nock, Michael Gilkey, Pingfu Fu, Nathan A. Pennell, Anant Madabhushi
Summary: Radiomic patterns extracted from CT images of patients with unresectable stage III NSCLC were found to be prognostic of progression-free survival (PFS) and overall survival (OS) outcomes following chemoradiotherapy (CRT) with durvalumab immunotherapy (IO) and CRT alone.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Shujing Wang, Hua Zhu, Yingjie Li, Jin Ding, Feng Wang, Lixin Ding, Xinyu Wang, Jun Zhao, Yan Zhang, Yunfeng Yao, Tong Zhou, Nan Li, Aiwen Wu, Zhi Yang
Summary: This study investigated the feasibility of using Zr-89-CTB006 PET/CT for noninvasive imaging of DR5 expression in cancer patients. The results of the clinical study showed that Zr-89-CTB006 PET/CT is capable of detecting DR5 expression and has potential for screening patients with DR5 overexpression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Gastroenterology & Hepatology
Wattana Leowattana, Tawithep Leowattana, PathompThep Leowattana
Summary: Recent studies have shown that the combination of immune checkpoint inhibitors and anti-angiogenic drugs improves survival in unresectable hepatocellular carcinoma (uHCC) patients, making it the recommended first-line therapy. Trans-arterial chemoembolization may be beneficial for intermediate-stage uHCC patients with retained liver function and no extrahepatic metastasis. Ongoing research indicates promising results for the combination therapy of immune checkpoint inhibitors and anti-angiogenic drugs.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Zi-Qiang Chu, Ke-Cheng Zhang, Lin Chen
Summary: Gastrointestinal (GI) cancer is a high-risk malignancy characterized by high mortality and morbidity. Inflammatory neutrophil extracellular traps (NETs) play an important role in cancer progression and metastasis, serving as potential prognostic markers and therapeutic targets in GI cancer.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Multidisciplinary Sciences
Chunyang Jiang, Xu Li, Bingsheng Sun, Na Zhang, Jing Li, Shijing Yue, Xiaoli Hu
Summary: This study demonstrates the role of ALAHM in tumor-derived extracellular vesicles (EVs) in promoting liver metastasis of lung adenocarcinoma (LUAD) cells. ALAHM enhances the proliferation, invasion, and migration of LUAD cells, and induces hepatocyte secretion of HGF. The findings suggest that LUAD-cell-derived EVs containing ALAHM contribute to the progression of liver metastasis in LUAD.
Article
Oncology
Zhenghang Wang, Qi Zhang, Changsong Qi, Yuezong Bai, Feilong Zhao, Hui Chen, Zhongwu Li, Xicheng Wang, Mifen Chen, Jifang Gong, Zhi Peng, Xiaotian Zhang, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Lin Shen, Jian Li
Summary: AKT1 and CDH1 mutations were identified as independent predictors of poor progression-free survival (PFS) and primary resistance to ICIs in dMMR/MSI-H GI cancer. The combination of these two genes as an immuno-oncology therapy predictor (IOpred) showed a high positive predictive value (PPV) and good performance in predicting primary resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Ryu Sasaki, Kazuyoshi Nagata, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Akihiko Soyama, Masaaki Hidaka, Susumu Eguchi, Masaya Shigeno, Mio Yamashima, Shinobu Yamamichi, Tatsuki Ichikawa, Yuki Kugiyama, Hiroshi Yatsuhashi, Kazuhiko Nakao
Summary: This study evaluated the use of liver-biliary phase of EOB-MRI to predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab. The results showed that in the lenvatinib group, the liver-biliary phase did not stratify progression-free survival (PFS) differently, while in the atezolizumab plus bevacizumab group, patients with heterogeneous type and hyperintensity type had significantly shorter PFS.
Review
Medicine, Research & Experimental
Kaiyue Xu, Huimin Guo, Anliang Xia, Zhangding Wang, Shouyu Wang, Qiang Wang
Summary: Radiotherapy is a crucial treatment for advanced solid tumors, including gastrointestinal cancer. However, resistance to radiotherapy poses a major challenge and limits therapeutic efficacy, leading to cancer recurrence and poor prognosis. To address this, there is an urgent need to identify novel biomarkers and therapeutic targets to understand the biological characteristics and mechanisms of radiotherapy resistance. Recent studies have shown that non-coding RNAs (ncRNAs) play a role in regulating radiotherapy resistance through various targets and pathways in different cancers. These findings offer potential strategies for overcoming radiotherapy resistance. This review highlights the recent findings on the functions and regulatory mechanisms of ncRNAs following radiotherapy, and discusses their potential as biomarkers and therapeutic targets in radiotherapy resistance of gastrointestinal cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Pathology
Hassan Abushukair, Obada Ababneh, Ayah Al-Bzour, Ibrahim Halil Sahin, Anwaar Saeed
Summary: This review discusses the applications of next-generation immunotherapy biomarkers, particularly in the context of GI cancers. It covers various aspects of currently used biomarkers and explores promising research on the next generation of biomarkers, addressing challenges in integrating them into clinical practice and the need for standardized protocols and guidelines.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2023)
Article
Geriatrics & Gerontology
Alessio Molfino, Marc Beltra, Maria Ida Amabile, Roberta Belli, Giovanni Birolo, Elena Belloni, Serena De Lucia, Lorena Garcia-Castillo, Fabio Penna, Giovanni Imbimbo, Giuseppe Nigri, Barbara Pardini, Paola Costelli, Maurizio Muscaritoli
Summary: This study analyzed small non-coding RNAs (sncRNAs) in patients with gastrointestinal cancer and found dysregulation of muscle-specific microRNAs in cancer-induced muscle wasting. The study also discovered an association between changes in circulating microRNAs and the level of muscularity at body composition analysis. SncRNAs in muscle were assessed by RNAseq, while circulating microRNAs were evaluated by qPCR.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Review
Cell Biology
Md Zahirul Islam Khan, Shing Yau Tam, Helen Ka Wai Law
Summary: Gastrointestinal cancers (GICs) are the most diagnosed cancers and the leading cause of cancer-related death globally. Deficiency of effective early diagnostic biomarkers contributes to poor prognosis and treatment outcomes. Proteomics study and its functional analysis hold promise in improving early diagnosis and management of GICs. Challenges remain in validating proteomics-based biomarkers for translation into clinical practice.
Article
Oncology
Kei Amioka, Tomokazu Kawaoka, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kensuke Naruto, Yuwa Ando, Yasutoshi Fujii, Shinsuke Uchikawa, Atsushi Ono, Masami Yamauchi, Michio Imamura, Yumi Kosaka, Kazuki Ohya, Nami Mori, Shintaro Takaki, Keiji Tsuji, Keiichi Masaki, Yoji Honda, Hirotaka Kouno, Hioshi Kohno, Kei Morio, Takashi Moriya, Noriaki Naeshiro, Michihiro Nonaka, Yasuyuki Aisaka, Takahiro Azakami, Akira Hiramatsu, Hiroshi Aikata, Shiro Oka
Summary: This study investigated the efficacy of lenvatinib and its combination with TACE in patients with intermediate-stage unresectable hepatocellular carcinoma (u-HCC). The results demonstrated the efficacy of lenvatinib and confirmed that further improvements in prognosis could be obtained with TACE after lenvatinib induction. This suggests that considering the combination of lenvatinib and TACE may be important for improving the prognosis of intermediate-stage u-HCC patients.
Article
Oncology
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Summary: Real-life data of cabozantinib for hepatocellular carcinoma in Italy showed comparable efficacy and safety with its registration trial. Factors such as macrovascular invasion, performance status, and alpha-fetoprotein level were associated with worse overall survival, while discontinuation for intolerance and absence of new extrahepatic lesions at progression were linked to better outcomes for patients.
Review
Oncology
Chenbin Liu, Han Wu, Yinqi Mao, Wei Chen, Shuying Chen
Summary: Exosomal microRNAs play a crucial role in hepatocellular carcinoma, holding significant value in the early diagnosis and treatment of this disease.
CANCER CELL INTERNATIONAL
(2021)
Article
Surgery
Andrew H. Nguyen, Michael P. O'Leary, James P. De Andrade, Philip G. Ituarte, Susanne G. Warner, Laleh G. Melstrom, Jonathan Kessler, Yuman Fong, Daneng Li, Gagandeep Singh
Summary: This population-based study examines the clinical and pathological characteristics of the youngest 5% of adult GEP-NETs patients. The findings suggest that young patients tend to have localized, well differentiated tumors and that early stage and surgical intervention are associated with lower mortality risk.
AMERICAN JOURNAL OF SURGERY
(2022)
Review
Geriatrics & Gerontology
Christiana Crook, Ya-Han Zhang, Daneng Li
Summary: Neuroendocrine tumors are rare and heterogeneous tumors that arise from hormone-producing cells throughout the body. The incidence of these tumors is highest among older adults aged 65 and above. However, there is a lack of data on the safety and efficacy of systemic treatment for older adults with neuroendocrine tumors. This review emphasizes the need for real-world data on tolerance in the older adult population and the development of novel systemic therapies for neuroendocrine tumors, with consideration for their impact on older adults.
Editorial Material
Oncology
Daneng Li, Ya-Han Zhang, Christiana J. Crook, Renuka V. Iyer
Review
Oncology
David C. Madoff, Nadine Abi-Jaoudeh, David Braxton, Lipika Goyal, Dhanpat Jain, Bruno C. Odisio, Riad Salem, Mark Schattner, Rahul Sheth, Daneng Li
Summary: This article outlines best practices and recommendations from a multidisciplinary team of experts to assist physicians involved in the care of patients with intrahepatic cholangiocarcinoma. It highlights the importance of biomarker testing in iCCA and the challenges associated with it, as well as suggesting best practices for optimizing tissue collection and biomarker testing.
Article
Oncology
Jacqueline Hsieh-Wong, James Liu, Jasmine Huynh, Mamta Parikh, Edward Kim, Jun Gong, Wissam Halabi, Mamatha Siricilla, Anupam Mitra, Kyra Toomey, May Cho
Summary: This case report highlights the importance of determining dMMR/MSI-H status in locally advanced rectal cancer (LARC) and the consideration of immunotherapy in treating synchronous primaries seen in inherited cancer syndromes. The patient in this case was diagnosed with dMMR/MSI-H LARC and synchronous upper tract urothelial cancer secondary to Lynch syndrome. After neoadjuvant chemotherapy and chemoradiation, the patient achieved only a partial pathologic response. However, after receiving adjuvant combination immunotherapy, the patient experienced a durable disease-free interval of nearly 21 months.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Oncology
Dae Won Kim, Young-Chul Kim, Bence P. Kovari, Vincent Chung, Olatunji B. Alese, Bassel F. El-Rayes, Daneng Li, Wungki Park, Richard D. Kim
Summary: This study suggests that PD-L1 expression on tumor, CD8 T cell infiltration, and the ratio of CD8/regulatory T cells, as well as a six-gene expression profile in the tumor microenvironment, may be potential predictive biomarkers for nivolumab in biliary tract cancers.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Daneng Li, Christina Darden, Noran Osman, Salma Sayeed, Laurin Jackson, Diana Garbinsky, Aman Chauhan
Summary: The study found that after 6 months of TE treatment, most patients were satisfied with the control of their carcinoid syndrome symptoms, and there was a significant improvement in the control of carcinoid syndrome diarrhea (CSD).
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Xuan Ge, Susan E. Yost, Jin Sun Lee, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Samuel Chung, Christina Yeon, Daphne Stewart, Daneng Li, Swapnil Rajurkar, George Somlo, Joanne Mortimer, James Waisman, Yuan Yuan
Summary: This study investigated the safety and antitumor activity of aromatase inhibitors (AIs) in combination with immune checkpoint inhibitor pembrolizumab in patients with HR+ HER2(-) metastatic breast cancer. The combination was well tolerated, but clinical activity was not significantly different from the use of AI alone.
Review
Oncology
Aman Chauhan, Jaydira Del Rivero, Robert A. Ramirez, Heloisa P. Soares, Daneng Li
Summary: Neuroendocrine tumors (NETs) are increasingly common, and the treatment options for advanced NETs are evolving rapidly. However, there is limited data on how different treatments should be sequenced. This review assesses clinical trial data and provides expert perspectives on treatment sequencing for various clinical scenarios. The best practices provided in this review can be helpful for clinicians considering treatment options for their patients with advanced NETs.
Article
Medicine, General & Internal
Christiana Joy Crook, Lisa Yen, Kathleen Ta, Misagh Karimi, Danny Nguyen, Richard T. Lee, Daneng Li
Summary: Neuroendocrine tumors are a rare type of cancer found in hormone-producing cells. However, there is a lack of research on disease-specific patient education assessments in this population. The NET VITALS tool has shown feasibility and validity in improving patient knowledge and communication. Incorporating NET VITALS into standard clinical care may enhance the overall clinical care experience for neuroendocrine tumor patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Weijie Ma, Jie Zeng, Dennis J. Montoya, Kyra Toomey, Chihong Zhou, Shuai Chen, Dingning Liu, Michael Babich, James A. Radosevich, Tianhong Li
Summary: Adenocarcinomas account for nearly 40% of all cancer types and are responsible for over 70% of cancer-related deaths. Labyrinthin (LAB) is a new cancer neoantigen expressed on the surface of adenocarcinoma cells in various cancer types. This study developed an immunohistochemistry assay to detect LAB expression in non-small-cell lung cancer (NSCLC) and investigated its clinical significance. Further research is needed to confirm LAB expression as a biomarker for selecting patients for LAB-targeted cancer therapy.
Review
Oncology
Luis A. Godoy, Joy Chen, Weijie Ma, Jag Lally, Kyra A. Toomey, Prabhu Rajappa, Roya Sheridan, Shirish Mahajan, Nicholas Stollenwerk, Chinh T. Phan, Danny Cheng, Robert J. Knebel, Tianhong Li
Summary: In the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC have significantly improved the survival and quality of life for patients with unresectable NSCLC. These biomarker-guided neoadjuvant therapies are also being used in patients with early-stage NSCLC, with the approval of neoadjuvant nivolumab and chemotherapy for stage IB-IIIA NSCLC. Ongoing trials are evaluating the efficacy of neoadjuvant immune checkpoint inhibitor combinations and neoadjuvant molecular targeted therapies for NSCLC.
BIOMARKER RESEARCH
(2023)
Article
Oncology
Daneng Li, Ruoding Tan, Sairy Hernandez, Norelle Reilly, Cooper Bussberg, Carol Mansfield
Summary: In patients with advanced hepatocellular carcinoma (HCC), avoiding severe hand-foot syndrome and high blood pressure is more important than prolonging survival. 10 additional months of maintaining daily function is considered equally or more important than 10 additional months of survival. For some patients with advanced HCC, maintaining quality of life and avoiding severe side effects is prioritized over the survival benefit of a treatment.
Editorial Material
Oncology
Abhishek Tripathi, Daneng Li, Sumanta K. Pal
Summary: Facchinetti and colleagues provide important insights into the development of resistance to FGFR inhibitors, including kinase domain mutations and PI3K-AKT signaling activation. In a separate study, Subbiah and colleagues report extensive preclinical and initial clinical data for RLY-4008, an FGFR2-selective inhibitor with greater potency and selectivity, which could minimize toxicity and overcome resistance.
Article
Oncology
Marc A. Attiyeh, Gautam K. Malhotra, Daneng Li, Saro B. Manoukian, Pejman M. Motarjem, Gagandeep Singh
Summary: This study compared the use of CT and MRI for staging metastatic colorectal or neuroendocrine liver metastases. The results showed that CT and MRI had no significant differences in lesion number or size for colorectal liver metastases. However, for neuroendocrine liver metastases, MRI outperformed CT in detecting more lesions and smaller lesions.
